

Duchenne Muscular Dystrophy (DMD)

**A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)**

<b>Trial Status</b> Recruiting	<b>Trial Runs In</b> 2 Countries	<b>Trial Identifier</b> NCT06128564 2022-000691-19 BN43881
-----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

***Trial Summary:***

This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.

<b>Hoffmann-La Roche</b> Sponsor	<b>Phase 2</b> Phase
<b>NCT06128564 2022-000691-19 BN43881</b> Trial Identifiers	

***Eligibility Criteria:***

<b>Gender</b> Male	<b>Age</b> <= 3 Years	<b>Healthy Volunteers</b> No
-----------------------	--------------------------	---------------------------------